Pharmaceutical powerhouse Eli Lilly’s ex-president has decided to sell his expansive Wyoming estate for a staggering $40 million, just as the company faced a setback with disappointing results from a weight loss drug trial. Dr. Jan Lundberg, who led Eli Lilly’s research labs and contributed significantly to the creation of the diabetes-turned-weight-loss drug Mounjaro, is parting ways with his grand mountain retreat in Jackson Hole, Wyoming.
Perched atop a private ridgeline in East Gros Ventre Butte, the estate boasts a 12,705-square-foot main residence, a four-bedroom guesthouse, and a tunnel connecting to a studio with a garage that can serve as staff quarters. The property, described as a “legacy retreat,” offers a unique blend of seclusion and accessibility, being a mere 15-minute drive from downtown Jackson while providing a serene sanctuary away from the hustle and bustle.
Approximately 70% of the acreage is under a conservation easement to maintain its scenic beauty and wildlife habitat, safeguarding it from extensive development. The main residence is lavishly equipped with nine bedrooms, 13 bathrooms, a three-tiered home theater, a gym with sauna and steam room, a game room, and an 1,800-bottle wine cellar with a tasting area. An indoor swimming pool and spa, complemented by a 45-kilowatt generator for off-grid readiness, ensure year-round comfort and luxury.
The estate boasts a rich wildlife presence, frequented by elk, moose, deer, and raptors, offering a unique connection to nature. Whether envisioned as a multigenerational retreat or a year-round basecamp, the property stands out as a once-in-a-generation investment opportunity. Lundberg, who mainly used the ranch as a vacation home, previously purchased a waterfront mansion in Florida, showcasing his diverse real estate portfolio.
During his tenure at Eli Lilly, Lundberg was instrumental in the development of Mounjaro and Trulicity, with Mounjaro transitioning from a diabetes treatment to a weight-loss drug. Following a weight loss trial setback, Eli Lilly’s shares plummeted by approximately 13%, contrasting with a surge in Novo Nordisk’s stock, a competitor in the oral obesity drug development space. Eli Lilly is committed to further investment in the weight loss drug orforglipron, with plans to seek FDA approval by the end of 2025.
Key Takeaways:
– Dr. Jan Lundberg, the former president of Eli Lilly, has listed his luxurious Wyoming ranch for $40 million amidst the company’s stock decline.
– The expansive estate features top-notch amenities, a conservation easement, and a rich wildlife habitat, making it an exceptional investment opportunity.
– Eli Lilly’s setback in a weight loss drug trial led to a stock drop, while the company remains dedicated to developing new weight loss treatments.
– Lundberg’s contributions to Eli Lilly’s drug development, particularly in the weight loss sector, have shaped the company’s pharmaceutical portfolio.
Read more on ourmidland.com